[go: up one dir, main page]

MX2009006685A - Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos. - Google Patents

Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.

Info

Publication number
MX2009006685A
MX2009006685A MX2009006685A MX2009006685A MX2009006685A MX 2009006685 A MX2009006685 A MX 2009006685A MX 2009006685 A MX2009006685 A MX 2009006685A MX 2009006685 A MX2009006685 A MX 2009006685A MX 2009006685 A MX2009006685 A MX 2009006685A
Authority
MX
Mexico
Prior art keywords
antagonists
neurological disorders
treating neurological
antibodies
immunoadhesins
Prior art date
Application number
MX2009006685A
Other languages
English (en)
Inventor
Anatoly Nikolaev
Marc Tessier-Lavigne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009006685A publication Critical patent/MX2009006685A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos y composiciones que comprenden antagonistas del DR6 para su uso en el tratamiento de trastornos neurológicos, incluida la enfermedad de Alzheimer. Los antagonistas del DR6 incluyen anticuerpos anti-APP, anticuerpos anti-DR6, inmunoadhesinas del DR6 y variantes del DR6 (y proteínas de fusión de las mismas) que potencian el crecimiento, la regeneración y la supervivencia de tejido o células neuronales.
MX2009006685A 2006-12-22 2007-12-21 Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos. MX2009006685A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87152806P 2006-12-22 2006-12-22
US90084807P 2007-02-12 2007-02-12
PCT/US2007/088521 WO2008080045A2 (en) 2006-12-22 2007-12-21 Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders

Publications (1)

Publication Number Publication Date
MX2009006685A true MX2009006685A (es) 2009-07-27

Family

ID=39535220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006685A MX2009006685A (es) 2006-12-22 2007-12-21 Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.

Country Status (19)

Country Link
US (1) US20100203044A1 (es)
EP (1) EP2094732A2 (es)
JP (1) JP2010514700A (es)
KR (1) KR20090094854A (es)
AR (1) AR064501A1 (es)
AU (1) AU2007336770A1 (es)
BR (1) BRPI0719459A2 (es)
CA (1) CA2671903A1 (es)
CL (1) CL2007003793A1 (es)
CO (1) CO6210755A2 (es)
MX (1) MX2009006685A (es)
NO (1) NO20092741L (es)
NZ (1) NZ577436A (es)
PE (1) PE20081546A1 (es)
RU (1) RU2009128039A (es)
SG (1) SG177924A1 (es)
TW (1) TW200844113A (es)
WO (1) WO2008080045A2 (es)
ZA (1) ZA201004219B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CA2821515A1 (en) 2010-12-01 2012-06-07 Alder Biopharmaceuticals, Inc. Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US20120238465A1 (en) * 2011-03-17 2012-09-20 Joseph Audie Drug screening target for alzheimer's disease and method of screening potential drugs
CN102708565A (zh) * 2012-05-07 2012-10-03 深圳市贝尔信智能系统有限公司 一种前景检测的方法、装置和系统
AU2014337504B2 (en) * 2013-10-14 2020-01-30 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
EP3072527B1 (en) 2013-11-20 2022-03-09 National University Corporation Hokkaido University Immunosuppressant
WO2015138698A1 (en) * 2014-03-12 2015-09-17 Temple University-Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
EP3685662B9 (en) 2015-03-16 2023-10-04 Regeneron Pharmaceuticals, Inc. Cell of a rodent exhibiting diminished upper and lower motor neuron function and sensory perception
EP3273982B1 (en) * 2015-03-26 2020-11-18 Suzhou Auzone Biological Technology Co., Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
US20190127476A1 (en) * 2016-05-06 2019-05-02 Abbvie Stemcentrx Llc Novel anti-tnfrsf21 antibodies and methods of use
KR102351126B1 (ko) * 2019-12-03 2022-01-13 재단법인대구경북과학기술원 App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702789A1 (de) * 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
CA2123211C (en) * 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US6013476A (en) * 1997-04-02 2000-01-11 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor TR7
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6949358B1 (en) 1997-06-11 2005-09-27 Human Genome Sciences, Inc. Human tumor necrosis factor receptor TR9
US7378507B2 (en) * 1997-09-18 2008-05-27 Genentech, Inc. PRO217 polypeptides
US6194151B1 (en) * 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
FR2778858B1 (fr) * 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6916907B1 (en) * 1998-10-23 2005-07-12 Curagen Corporation Nucleic acids encoding osteoprotegern-like proteins and methods of using same
US6423494B1 (en) * 1999-03-25 2002-07-23 Millennium Pharmaceuticals, Inc. DR6 and uses thereof
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
AU2002255881A1 (en) * 2001-03-23 2002-10-08 University Of Utah Research Foundation Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
WO2003039467A2 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
WO2003040183A2 (en) * 2001-11-09 2003-05-15 The Genetics Company, Inc Compounds for the diagnosis/prevention/treatment of alzheimer's disease
AU2002359459A1 (en) * 2001-12-17 2003-06-30 Eli Lilly And Company Treating b-cell mediated diseases by modulating dr6 activity
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
ES2301280A1 (es) * 2005-05-16 2008-06-16 Fina Biotech S.L.U. Metodo para diagnosticar la enfermedad de alzheimer.
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density

Also Published As

Publication number Publication date
RU2009128039A (ru) 2011-01-27
NZ577436A (en) 2012-05-25
CL2007003793A1 (es) 2008-07-25
WO2008080045A3 (en) 2008-09-12
SG177924A1 (en) 2012-02-28
PE20081546A1 (es) 2008-12-22
KR20090094854A (ko) 2009-09-08
AR064501A1 (es) 2009-04-08
ZA201004219B (en) 2013-02-27
EP2094732A2 (en) 2009-09-02
NO20092741L (no) 2009-09-21
CA2671903A1 (en) 2008-07-03
CO6210755A2 (es) 2010-10-20
WO2008080045A2 (en) 2008-07-03
TW200844113A (en) 2008-11-16
JP2010514700A (ja) 2010-05-06
US20100203044A1 (en) 2010-08-12
AU2007336770A1 (en) 2008-07-03
BRPI0719459A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
MX2009006685A (es) Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.
IL267126B (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2005063820A3 (en) Il-7 fusion proteins
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
EP2441847A3 (en) Screening methods using syk in combination with tau protein
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
GEP20166454B (en) Sclerostin binding agents
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
IL186228A0 (en) Preparation of autologous haematopoietic stem cells, the methods of production, cryopreservation and use for therapy of traumatic diseases of the central nervous system
WO2009149485A3 (en) Compounds for treating amyloidoses
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2005115548A3 (en) Treating depressive disorders with carbonic anhydrase activators
MX2007013834A (es) Terapias de enfermedades vasculares.
WO2008061209A3 (en) G protein coupled receptors and uses thereof
WO2007035722A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
WO2007143578A3 (en) Perforin-2 proteins
WO2005074972A3 (en) Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal